In January, 2019 in a stock swap AmpliPhi Biosciences Corporation (NYSEMKT:APHB) - founded in 1989 - effected a reverse merging with fellow infectious disease-focused firm C3J Therapeutics Inc with C3J surviving as a wholly owned subsidiary of AmpliPhi. Anchored in tcehnology licensed form UCLA , C3 Jian, Inc., had been a clinical-stage biotechnology, develops and commercializes products to diagnose, treat, and prevent human and animal diseases. The firm's lead compounds oranized around treatment of bacterial and fungal infections, and disorders of mineralization. The company, through its subsidiary, Intelliherb, also provides herbal and botanical products, such as sugar-free cavity-fighting herbal lollipops; and products for treatment of dental infections, eradication of H. pylori, management of obesity and cholesterol levels, to kill skin bacteria causing body odor, and for personal hygiene
